Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sequana Medical NVFRA:2SE 31 3-Year ROIIC % is 9.09 as of Dec. 2024, which is at its 10-year median of 9.09. GuruFocus rates FRA:2SE with a GF Score™ of 31/100 and a GF Value™ of €0.19. The stock has 12 warning signs investors should review. Among 797 Medical Devices & Instruments companies, Sequana Medical NV ranks better than 59.6% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Sequana Medical NV's 3-Year ROIIC % for the quarter that ended in Dec. 2024 was 9.09%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Sequana Medical NV's 3-Year ROIIC % or its related term are showing as below:
FRA:2SE's 3-Year ROIIC % is ranked better than 59.6% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 1.47
vs FRA:2SE: 9.09
Sequana Medical NV (FRA:2SE) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Sequana Medical NV 3-Year ROIIC % Related Terms
Sequana Medical NV 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Sequana Medical NV's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2SE vs ABT, SYK, MDT: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, Sequana Medical NV's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sequana Medical NV 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sequana Medical NV's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Sequana Medical NV's 3-Year ROIIC % falls into.
Sequana Medical NV's 3-Year ROIIC % for the quarter that ended in Dec. 2024 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -18.223 (Dec. 2024) - -22.614 (Dec. 2021) )
/
( 53.156 (Dec. 2024) - 4.876 (Dec. 2021) )
=
4.391
/
48.28
=
9.09%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Sequana Medical NV (FRA:2SE) has a 3-Year ROIIC % of 9.09 as of Dec. 2024. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sequana Medical NV and its competitors. This is near median its historical median of 9.09. According to the industry distribution chart, Sequana Medical NV ranks #322 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 40.4%.
Is Sequana Medical NV's 3-Year ROIIC % too high?
Sequana Medical NV's current 3-Year ROIIC % of 9.09 is near median its 10-year median of 9.09. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.47. Sequana Medical NV's value of 9.09 is 518.4% above this industry median. Based on the distribution chart, Sequana Medical NV ranks #322 out of 797 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sequana Medical NV has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Sequana Medical NV's 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sequana Medical NV ranks #322 out of 797 companies for 3-Year ROIIC %. This puts Sequana Medical NV in the upper half of its industry. The industry median 3-Year ROIIC % is 1.47. Sequana Medical NV's value of 9.09 is 518.4% above this benchmark. While the company's 10-year median is 9.09 vs. the industry median of 1.47, Sequana Medical NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.47, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sequana Medical NV's current 3-Year ROIIC % of 9.09 is 518.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sequana Medical NV and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sequana Medical NV's current 3-Year ROIIC % is 9.09, which is near median its own 10-year median of 9.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sequana Medical NV stock overvalued right now?
Sequana Medical NV (FRA:2SE) has a current 3-Year ROIIC % of 9.09. The stock's GF Value™ is €0.19, compared to a current price of €0.51 — trading 169.5% above its estimated fair value. The current 3-Year ROIIC % is 9.09, which is near median its 10-year median of 9.09 and 518.4% above the Medical Devices & Instruments industry median of 1.47. Sequana Medical NV's overall GF Score™ is 31/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Sequana Medical NV (FRA:2SE), the current 3-Year ROIIC % is 9.09 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sequana Medical NV (FRA:2SE) Overvalued in 2026?
Based on GuruFocus' analysis, Sequana Medical NV stock appears to be overvalued.
The current stock price of €0.51 is trading 169.5% above its estimated GF Value™ of €0.19.
Key valuation signals for FRA:2SE:
3-Year ROIIC %: 9.09 (near median its 10-year median of 9.09)
GF Value™: €0.19 vs. price of €0.51 (169.5% above fair value)
Industry Position: 518.4% above the Medical Devices & Instruments median (#322 of 797)
No single metric tells the full story. See the FRA:2SE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies. The company's geographical segments include Switzerland, Germany, the United Kingdom, France, and the Rest of the world, out of which Germany accounts for the majority of the revenue.
31GF Score
Get the complete analysis for FRA:2SE
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2SE has been successfully added to your 
